PubMed Health⌕ Search

Biomedical subjects

R Gerzer

Publications and source records attributed to R Gerzer.

143 records · Page 8Linked to original sources
PubMed1986

Mechanisms of action of atrial natriuretic factor: clinical consequences.

Atrial natriuretic factor (ANF) acts through specific receptors at its target tissues. Receptor-occupancy by ANF induces activation of particulate guanylate cyclase, increased cyclic GMP formation and also inhibition of adenylate cyclase which results in a decrease of cyclic AMP formation. These second messenger systems appear to mediate the effects of ANF in target tissues. Following receptor-mediated activation of particulate guanylate cyclase, cyclic GMP is extruded from the cells, which leads to elevated cyclic GMP levels in plasma and urine in man, whereas cyclic AMP levels remain unchanged. Since cyclic GMP has a much longer half-life than ANF, it is more sensitive as a marker for ANF release than ANF itself, which has a half-life of just a few minutes. Since cyclic GMP is excreted into urine, determinations of urine cyclic GMP can also allow conclusions about the ANF system when blood sampling is impractical. Thus, cyclic GMP and not cyclic AMP is a sensitive biological marker for ANF.

Adenylyl Cyclases↗
PubMed1985

Concomitant increase in plasma atrial natriuretic peptide and cyclic GMP during volume loading.

To investigate the effects of fluid expansion on endogenous atrial natriuretic peptide (ANP) and cyclic 3',5'-guanosine monophosphate (cGMP), four male volunteers were studied before, during and after intravasal volume loading. Volume expansion was performed by intravenous infusion of 2,000 ml isotonic saline solution within 30 min. Mean plasma ANP levels increased 2.5-fold from 31.2 pg/ml to 81.7 pg/ml 40 min after the start of infusion. Plasma cGMP levels paralleled the rise in ANP, showing a mean cGMP increment from 2.7 pmol/ml to a maximum of 8.2 pmol/ml. Both ANP and cGMP levels were back to basal levels 120 min after termination of the infusion. Stimulation of endogenous ANP release by volume loading suggests that ANP is involved in the regulation of fluid homeostasis in man. The parallel rise in plasma cGMP levels supports the idea that cGMP is a mediator for the effects of ANP.

Adult↗
PubMed1985

[The heart as an endocrine organ: the discovery of a new hormone].

Ever since the early work of Henry and Gauer (1956) it has been clear that a link exists between the atria of mammals and diuresis. In 1981, De Bold et al. described that atrial extracts, injected intravenously into rats, caused diuresis. The hormone responsible for this diuresis has quickly been identified. The peptide hormone, atrial natriuretic factor (ANF), which is also known as atrial natriuretic peptide(s) (ANP), cardionatrin, cardiodilatin, atrin or auriculin, has been sequenced and synthetically produced. Its genomic DNA has been cloned. ANF raises cyclic GMP in target cells and activates particulate guanylate cyclase but not soluble guanylate cyclase. So far, no other hormone has conclusively been shown to activate particulate guanylate cyclase. ANF is formed and secreted in the atria but not in the ventricles of mammals, including man. The action of ANF involves natriuresis, vasorelaxation and inhibition of aldosterone secretion. ANF or ANF derivatives may represent a therapeutically useful new class of agents.

Adrenal Glands↗
PubMed1985

The increase of cGMP by atrial natriuretic factor correlates with the distribution of particulate guanylate cyclase.

We have demonstrated previously that atrial natriuretic factor (ANF) augments urinary, plasma and kidney cGMP levels but has no significant effect upon cAMP. Using cGMP as a marker, we searched for specific target sites involved in the action of ANF in the dog kidney, and observed no change of cGMP in the proximal tubules, a 2-fold increase over basal levels in the thick loop of Henle and a 3-fold elevation in the collecting duct. The most striking action on cGMP occurred in the glomeruli with a rise of up to 50-fold being evident at 1-2 min. after the addition of ANF. The results obtained in the absence or presence of a phosphodiesterase inhibitor support the notion that the effects of ANF were exerted at the level of guanylate cyclase stimulation rather than cGMP phosphodiesterase inhibition. The action of sodium nitroprusside (SNP), a direct stimulator of soluble guanylate cyclase, differed from that of ANF. The ability of the factor to enhance cGMP levels was correlated with the distribution of particulate guanylate cyclase. This study identifies the glomeruli and the distal part of the nephron as specific targets of ANF and implicates particulate guanylate cyclase as the enzyme targetted for the expression of its action.

Animals↗
PubMed1985

Rapid increase in plasma and urinary cyclic GMP after bolus injection of atrial natriuretic factor in man.

We studied the effects of a bolus injection of 50/micrograms synthetic human atrial natriuretic factor (ANF) on the cyclic GMP and cyclic AMP levels in plasma and urine of eight normal men. Administration of the hormone increased basal immunoreactive (IR-) ANF levels in plasma 2.8-fold to 110 pM three minutes after injection. Thereafter, IR-ANF levels rapidly declined to basal levels. Plasma cyclic GMP levels increased 2.6-fold to 16.6 nM within 6 minutes after ANF and decreased to near basal values within 30 minutes. Urinary cyclic GMP excretion increased 2.8-fold, whereas urinary volume and sodium excretion increased less than two-fold in the 30 minutes after ANF. Plasma cyclic AMP levels did not change. The data indicate that changes in plasma IR-ANF levels are followed by changes in plasma cyclic GMP and in urinary cyclic GMP excretion and suggest that cyclic GMP is a biological marker for circulating ANF in man.

Adult↗
PubMed1983

Purification and characterization of particulate guanylate cyclase from sea urchin spermatozoa.

The particulate form of guanylate cyclase from sea urchin spermatozoa was purified to apparent homogeneity by chromatography on GTP-Sepharose and DEAE-Sepharose and by preparative gel electrophoresis. The sedimentation coefficient (S20,w) was 6.8 and the Stokes radius was 5.1 nm, from which a native molecular weight of 157,000 was calculated. A single protein or periodic acid-Schiff staining band of 135,000 Da was observed after Na dodecyl SO4 gel electrophoresis. Antibody was produced to guanylate cyclase and was shown by electrophoretic transfer experiments (Western blot) to interact with only the Mr = 135,000 band in cases where all of the detergent-extracted protein from spermatozoa was added to the Na dodecyl SO4 gels. Although guanylate cyclase was normally bound to concanavalin A-Sepharose, after endoglycosidase H treatment it failed to bind. Treatment of the enzyme with endoglycosidase H did not alter guanylate cyclase activity, but the apparent size of the enzyme decreased to 72,000 Da on Na dodecyl SO4 gels. An analysis of carbohydrate composition indicated that the oligosaccharides contained N-acetylglucosamine, mannose, galactose, and 2-aminoerythritol in molar ratios (1:3:0.75:2); after endoglycosidase H treatment the enzyme contained essentially no carbohydrate. Major amino acids in the enzyme were aspartic (Asn) and glutamic (Gln) which accounted for approximately 25 mol % of the enzyme amino acid composition. The purified enzyme displayed linear kinetics on double reciprocal plots and had a KMnGTP = 133 microM, KM2+ = 138 microM, KiMnGTP = 122 microM, KiMn2+ = 127 microM, and a V max in excess of 15 mumol of cyclic GMP formed/min/mg of protein at 30 degrees C. Sodium nitroprusside did not stimulate the enzyme in either the presence or absence of added hemeproteins. These results indicate that the particulate form of guanylate cyclase from sea urchin spermatozoa is a glycoprotein which is distinctly different than the soluble form of the enzyme found in mammalian tissues.

Amino Acids↗
PubMed1983

Calcium-induced release from platelet membranes of fatty acids that modulate soluble guanylate cyclase.

Incubation of rat or rabbit platelet membranes with Ca++ induced the release of modulators of soluble guanylate cyclase. These modulators increased basal activity and inhibited sodium nitroprusside-stimulated activity in the absence or presence of dithiothreitol. The release, but not the effects, of the modulators was inhibited by trifluoperazine and by mepacrine. Indomethacin and oxyphenbutazone did not influence the release or effects of the modulators. The factors were identified as arachidonic and linoleic acids. These fatty acids produced comparable effects on crude soluble guanylate cyclase from platelets and on the homogeneously purified enzyme from bovine lung. In the presence of MgCl2, the maximal increase in basal activity was observed at 10 to 30 microM arachidonic or linoleic acid with the crude enzyme and at 3 to 6 microM with the purified enzyme. Inhibition of basal activity was observed at higher concentrations. Half-maximal inhibition of Mg++-supported, sodium nitroprusside-augmented activity was observed at 3 to 10 microM fatty acid. The effects of arachidonic acid occurred without a lag period and were quickly reversible. These data demonstrate that unsaturated fatty acids can be released from platelet membranes by a Ca++-dependent process in amounts that are high enough to alter soluble guanylate cyclase activity. The data also indicate that unsaturated fatty acids exert their effects on soluble guanylate cyclase without having to be converted to peroxides by other enzymes.

Animals↗
PubMed1981

Purification of a soluble, sodium-nitroprusside-stimulated guanylate cyclase from bovine lung.

A soluble, sodium-nitroprusside-stimulated guanylate cyclase as been purified from bovine lung by DEAE-cellulose chromatography, ammonium sulfate precipitation, chromatography on Blue Sepharose CL-6B and preparative gel electrophoresis. Apparent homogeneity was obtained after at least 7000-fold purification with a yield of 3%. A single stained band (Mr 72000) was observed after gel electrophoresis in the presence of sodium dodecyl sulfate. The purified enzyme migrated as one band also under non-denaturing conditions in acrylamide gels (5-12%). The mobility of this band corresponded to an Mr of 145000. The enzyme sedimented on sucrose gradients with an S20, w of 7.0 S. Gel filtration yielded a Stokes' radius of 4.6 nm. These data suggest that the enzyme has an Mr of approximately 150000 and consists of two, presumably identical, subunits of Mr 72000. Sodium nitroprusside stimulated the purified enzyme 15-fold and 140-fold to specific activities of 8.5 and 15.7 mumol of cGMP formed min-1 mg-1 in the presence of Mn2+ and Mg2+, respectively. Formation of cGMP was proportional to the incubation time and to the amount of enzyme added. The stimulatory effect of sodium nitroprusside was half-maximal at about 2 microM, was observed immediately after addition and could be reversed either by dilution or by removal of sodium nitroprusside on a Sephadex G-25 column. The purified enzyme in the absence of catalase was stimulated by sodium nitroprusside, N-methyl-N'-nitro-N-nitrosoguanidine and 3-morpholino-sydnonimine and in the presence of catalase by sodium nitrite and sodium azide. In the presence of Mn2+ and sodium nitroprusside, the purified enzyme catalyzed the formation of cAMP from ATP at a rate of 0.6 mumol min-1 mg-1.

Animals↗
PubMedDate not supplied

Critical issues in connection with human planetary missions: protection of and from the environment.

Activities associated with human missions to the Moon or to Mars will interact with the environment in two reciprocal ways: (i) the mission needs to be protected from the natural environmental elements that can be harmful to human health, the equipment or to their operations: (ii) the specific natural environment of the Moon or Mars should be protected so that it retains its value for scientific and other purposes. The following environmental elements need to be considered in order to protect humans and the equipment on the planetary surface: (i) cosmic ionizing radiation, (ii) solar particle events; (iii) solar ultraviolet radiation; (iv) reduced gravity; (v) thin atmosphere; (vi) extremes in temperatures and their fluctuations; (vii) surface dust; (viii) impacts by meteorites and micrometeorites. In order to protect the planetary environment. the requirements for planetary protection as adopted by COSPAR for lander missions need to be revised in view of human presence on the planet. Landers carrying equipment for exobiological investigations require special consideration to reduce contamination by terrestrial microorganisms and organic matter to the Greatest feasible extent. Records of human activities on the planet's surface should be maintained in sufficient detail that future scientific experimenters can determine whether environmental modifications have resulted from explorations. Grant numbers: 14056/99/NL/PA.

Aerospace Medicine↗
PubMedDate not supplied

Telemedicine for the International Space Station.

The medical care for the integrated crew of the International Space Station (ISS) will require close co-operation between the partner agencies in the areas of selection, medical surveillance, countermeasures, and handling of acute medical problems. Based on a commonly accepted policy of shared care and responsibilities medical guidelines, procedures, and standards for medical data and communication need to be harmonised under the responsibility of the Multilateral Medical Operations Panel (MMOP). A supporting telemedical network connecting the partners on an organisational and technical level will facilitate the harmonisation process and provide new tools for effective co-operation between medical professionals. Earth bound projects with similar application areas can profit from and contribute to this development and need to be considered for efficient implementation and exploitation.

Aerospace Medicine↗
PubMedDate not supplied

Characterization of subtypes of hypertension in CAPD patients by cyclic guanosine monophosphate.

OBJECTIVE: While most hypertensive patients with end-stage renal disease normalize high blood pressure with fluid removal by continuous ambulatory peritoneal dialysis (CAPD), there is a significant proportion of CAPD patients whose blood pressure can be controlled only by antihypertensive drugs. METHOD AND PATIENTS: To study the hypothesis that such patients are still volume overloaded, we used plasma cyclic guanosine monophosphate (cGMP) as a marker for hydration status. Thirty-two CAPD patients were divided into 3 groups: group 1, normotensive patients (n = 12); group 2, hypertensive patients who normalized their blood pressure with fluid removal (n = 12); group 3, hypertensive patients whose blood pressure was refractory to intensified fluid removal (n = 8). RESULTS: Mean cGMP levels were significantly higher in dialysis-sensitive hypertension (27 +/- 5 pmol/mL) than in dialysis-refractory hypertension (15 +/- 2 pmol/mL), or in normotensive patients (13 +/- 4 pmol/mL). Reduction of excess fluid in volume overloaded hypertensive CAPD patients resulted in a normalization of cGMP levels (14 +/- 8 pmol/mL), but did not affect this volume marker in patients with dialysis-resistant hypertension (10 +/- 4 pmol/mL). CONCLUSION: Plasma cGMP levels are elevated in volume overload-induced hypertension complicating CAPD. Hypertensive CAPD patients whose plasma cGMP levels are within normal limits have raised blood pressure refractory to volume removal. Our findings are consistent with the hypothesis that inadequate removal of excess volume plays a major role in a subset of patients with CAPD hypertension.

Blood Pressure↗